Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA)

Fig. 3

Weighted value contribution of selexipag for the treatment of PAH compared to iloprost according to quantitative criteria of the adapted MCDA framework. Mean value contributions of each quantitative criterion and overall MCDA value estimates for selexipag in the PAH treatment are shown. Error bars show standard deviations across the 28 study participants

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172